Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The myc proto-oncogenes are transcription factors that directly regulate the expression of other genes, by binding to the specific DNA sequence, CACGTG. Among the target genes for
c-Myc
regulation are ECA39, p53,
ornithine decarboxylase
(
ODC
), alpha-prothymosin and Cdc25A. In this study we examined the involvement of
c-Myc
target genes in human oncogenesis induced by c-myc or N-myc. In MCF-7 breast cancer cells, the induction of c-myc expression by estrogen was followed by the induction of all the Myc targets that we examined, indicating that those genes can serve as
c-Myc
targets in human oncogenesis. Moreover, in breast tumors exhibiting c-myc overexpression, several Myc targets were also overexpressed. A clear correlation between the expression of c-myc and its targets was also detected in Burkitt's lymphomas, which involve a specific translocation of c-myc gene, but not in other lymphoma cells. Yet, in cells derived from a neuronal origin the pattern of expression of Myc targets was more complex. In a neuroepithelioma cell line that overexpresses c-myc, only some targets were expressed. In addition in neuroblastomas, in which N-myc is amplified and overexpressed, only
ODC
was overexpressed in all cell lines, while all other target genes were expressed in only some of the cell lines. The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for
c-Myc
regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes.
...
PMID:Involvement of Myc targets in c-myc and N-myc induced human tumors. 967
Ras-activated signal transduction pathways are implicated in the control of cell proliferation, differentiation, apoptosis, and tumorigenesis, but the molecular mechanisms mediating these diverse functions have yet to be fully elucidated. Conditionally active forms of Raf, v-Src, and MEK1 were used to identify changes in gene expression that participate in oncogenic transformation, as well as in normal growth control. Activation of Raf, v-Src, and MEK1 led to induced expression of
c-Myc
and cyclin D1. Induction of
c-Myc
mRNA by Raf was an immediate-early response, whereas the induction of cyclin D1 mRNA was delayed and inhibited by cycloheximide. Raf activation also resulted in the induction of an established
c-Myc
target gene,
ornithine decarboxylase
(
ODC
).
ODC
induction by Raf was mediated, in part, by tandem E-boxes contained in the first intron of the gene. Activation of the human colony-stimulating factor 1 (CSF-1) receptor in NIH 3T3 cells leads to activation of the mitogen-activated protein (MAP) kinase pathway and induced expression of c-Fos,
c-Myc
, and cyclin D1, leading to a potent mitogenic response. By contrast, a mutated form of this receptor fails to activate the MAP kinases or induce
c-Myc
and cyclin D1 expression and fails to elicit a mitogenic response. The biological significance of
c-Myc
and cyclin D1 induction by Raf and v-Src was confirmed by the demonstration that both of these protein kinases complemented the signaling and mitogenic defects of cells expressing this mutated form of the human CSF-1 receptor. Furthermore, the induction of
c-Myc
and cyclin D1 by oncogenes and growth factors was inhibited by PD098059, a specific MAP kinase kinase (MEK) inhibitor. These data suggest that the Raf/MEK/MAP kinase pathway plays an important role in the regulation of
c-Myc
and cyclin D1 expression in NIH 3T3 cells. The ability of oncogenes such as Raf and v-Src to regulate the expression of these proteins reveals new lines of communication between cytosolic signal transducers and the cell cycle machinery.
...
PMID:Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. 989 Oct 45
Starting with an extract derived from the bark of Mundulea sericea Willd. (Leguminosae) that was active in the process of inhibiting 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced
ornithine decarboxylase
activity (ODC) in cultured mouse epidermal ME 308 cells, the isoflavonoid munetone was isolated and identified as an active principle (IC50 = 46 ng/ml). Topical application of munetone (0.04-5 micromol) to the skin of CD-1 mice 2 h prior to treatment with TPA (10 nmol) resulted in dose-dependent inhibition of epidermal ODC activity. In addition, munetone inhibited TPA-independent
c-Myc
-induced ODC activity with cultured BALB/c c-MycER cells, as well as 7,12-dimethylbenz[a]anthracene (DMBA)-induced preneoplastic lesion formation in a mouse mammary gland organ culture (MMOC) system. These data suggest the potential of munetone to serve as a cancer chemopreventive agent by virtue of blocking the process of tumor promotion.
...
PMID:Inhibitory effect of munetone, an isoflavonoid, on 12-O-tetradecanoylphorbol 13-acetate-induced ornithine decarboxylase activity. 1021 40
The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been recently identified to be a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nuclear retinoic acid receptor independent mechanism. To approach the mechanism by which CD437 induces apoptosis in NSCLC cells, we investigated the involvement of
c-Myc
in CD437-induced apoptosis. CD437 (1 microM) up-regulated the expression of
c-Myc
and of its downstream target genes
ornithine decarboxylase
(
ODC
) and cdc25A in all three NSCLC cell lines (i.e., H460, SK-MES-1 and H1792) used. These effects were correlated with cellular susceptibilities to induction of apoptosis by CD437. Furthermore, CD437-induced apoptosis could be blocked by the
ODC
inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FMK and Z-DEVD FMK, and
c-Myc
antisense oligodeoxynucleotide, respectively. These data indicate that
c-Myc
gene plays an important role in mediating CD437-induced apoptosis in human NSCLC cells.
...
PMID:Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. 1044 53
Expression of
ornithine decarboxylase
(
ODC
) is induced by
c-Myc
oncoprotein and is required for cell proliferation and tumour growth. We have studied the expression of
ODC
mRNA by in situ hybridisation and in situ RT-PCR in archival human hyperplastic breast tissues. A very low signal was detected by in situ hybridisation, while the in situ RT-PCR on human breast archival tissues demonstrated an over-expression of
ODC
mRNA in epithelial cells characterised by some degree of hyperplasia, maintaining the morphology of the archival tissue intact despite the multiple steps of fixation, permeabilization and thermal cycling.
...
PMID:In situ RT-PCR allows the detection of ornithine decarboxylase mRNA in paraffin embedded archival human hyperplastic breast tissues. 1056 50
The
ornithine decarboxylase
(
ODC
) gene is a transcriptional target of
c-Myc
. Exponentially growing cells usually exhibit high
c-Myc
levels and high
ODC
levels, whereas stationary phase cells and terminally differentiated cells have low levels of both proteins. Therefore, we were surprised to find that when F9 teratocarcinoma stem cells were blocked in the G(1) phase of their cell cycle and induced to differentiate by irreversible inhibition of the
ODC
activity, the expression of
c-Myc
was up-regulated instead of being down-regulated. During the course of differentiation, the c-myc gene was constitutively expressed, and
c-Myc
protein accumulated. In transfection experiments, using
ODC
promoter-reporter gene fusion constructs, the accumulation of
c-Myc
protein, resulting from polyamine depletion, led to increased reporter gene expression. This finding is consistent with the view that depletion of polyamines relieves the suppression that they exert on c-myc mRNA translation, causing an accumulation of
c-Myc
protein, which in turn transactivates its target gene, the bona fide
ODC
gene. Thus, the accumulation of an active
c-Myc
protein does not preclude differentiative events, nor does it override the growth arrest caused by polyamine depletion. These results suggest a new role for polyamines-as negative regulators of
c-Myc
expression.
...
PMID:Polyamine depletion up-regulates c-Myc expression, yet induces G(1) arrest and terminal differentiation of F9 teratocarcinoma stem cells. 1058 Oct 8
Over-expression of the transcription factor
c-Myc
immortalizes primary cells and transforms in co-operation with activated ras. Therefore, c-myc is considered a proto-oncogene. Since its discovery
c-Myc
has been shown to render cells growth factor independent, accelerates passage through G1 of the cell cycle, inhibits differentiation and elicits apoptosis. Whereas the effects on immortalization, proliferation and inhibition of differentiation are in conceivable accordance with gain of function, as it is defined for a proto-oncogene, its pro-apoptotic activity disables a straight forward explanation of the physiological role of
c-Myc
and suggests a highly complex contribution during development. The recent accomplishments in
c-Myc
research shed some light on the difficile regulatory network which keeps check on
c-Myc
activity such as by binding to proteins some of which are transcription factors for non-
c-Myc
targets. Moreover, it was shown that genes are targeted by
c-Myc
depending on the sequence of flanking regions adjacent to the E-box or in dependence on the availability of binding partners which is most probably specific to the cellular context. Cdc25A and
ornithine decarboxylase
, both described to be
c-Myc
targets, have been brought forward as downstream effectors in the induction of proliferation under serum rich conditions, or in the induction of apoptosis when serum factors are limited. These genes seem to be regulated by
c-Myc
in a cell type-specific manner. H-ferritin, IRP2 and telomerase are the most recently discovered direct targets of
c-Myc
. The regulation of H-ferritin and IRP2 might explain the potential of
c-Myc
to promote proliferation and the regulation of telomerase could be responsible for the immortalizing properties of
c-Myc
. In the future, H-ferritin and telomerase have to be analyzed whether or not these genes are also Myc targets in other cell systems. Although the intense research efforts regarding the function of
c-Myc
last already two decades the role of this gene is still enigmatic.
...
PMID:The MYC dualism in growth and death. 1059 28
We have studied the expression of
ornithine decarboxylase
(
ODC
) mRNA by in situ hybridization and in situ RT-PCR in human breast cancer MCF-7 cell line. In situ RT-PCR demonstrated the overexpression of
ODC
mRNA, localized over the cytoplasm, while a very low signal was detected by in situ hybridization. Our findings indicate that in situ RT-PCR could represent a useful tool to study different levels of
ODC
expression in normal and tumor tissues. Since
ODC
expression is regulated by
c-Myc
oncoprotein, this model could be useful to monitor in vivo the effects of new anti-neoplastic molecules, specific inhibitors of
c-Myc
.
...
PMID:Detection of ornithine decarboxylase mRNA in human breast cancer MCF-7 cells by in situ RT-PCR. 1063 65
Analysis of amino-terminus mutants of
c-Myc
has allowed a systematic study of the interrelationship between Myc's ability to regulate transcription and its apoptotic, proliferative, and transforming functions. First, we have found that
c-Myc
-accelerated apoptosis does not directly correlate with its ability to transactivate transcription using the endogenous
ornithine decarboxylase
(
ODC
) gene as readout for transactivation. Furthermore, deletion of the conserved
c-Myc
box I domain implicated in transactivation does not inhibit apoptosis. Second, the ability of
c-Myc
to repress transcription, using the gadd45 gene as a readout, correlates with its ability to accelerate apoptosis. A conserved region of
c-Myc
implicated in mediating transrepression is absolutely required for
c-Myc
-accelerated apoptosis. Third, a lymphoma-derived Thr58Ala mutation diminishes
c-Myc
-accelerated apoptosis through a decreased ability to induce the release of cytochrome c from mitochondria. This mutation in a potential phosphorylation site does not affect cell cycle progression, providing genetic evidence that induction of cell cycle progression and acceleration of apoptosis are two separable functions of
c-Myc
. Finally, we show that the increased ability of Thr58Ala mutant to elicit cellular transformation correlates with its diminished ability to accelerate apoptosis. Bcl-2 overexpression blocked and the lymphoma-associated Thr58Ala mutation decreased
c-Myc
-accelerated apoptosis, and both led to a significant increase in the ability of Rat1a cells to form colonies in soft agar. This enhanced transformation was greater in soft agar containing a low concentration of serum, suggesting that protection from apoptosis is a mechanism contributing to the increased ability of these cells to proliferate in suspension. Thus, we show here for the first time that, in addition to mutations in complementary antiapoptotic genes,
c-Myc
itself can acquire mutations that potentiate neoplastic transformation by affecting apoptosis independently of cell cycle progression.
...
PMID:Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. 1091 83
Cell number is regulated by maintaining a balance between cell proliferation and cell death through apoptosis. Key regulators of this balance include the oncogene product
c-Myc
, which promotes either entry into the cell cycle or apoptosis [1]. Although the mechanism of
c-Myc
-induced apoptosis remains unclear, it is susceptible to regulation by survival factors [2,3] and can proceed through the interaction of Fas ligand (FasL) with its receptor, Fas [4]. Activated T lymphocytes are eliminated by an apoptotic process known as activation-induced cell death (AICD), which requires the transcriptional induction of FasL expression [5-7] and sustained levels of
c-Myc
[8]. The FasL promoter can be driven by
c-Myc
overexpression, and functional inhibitors of Myc and its binding partner, Max, inhibit the transcriptional activity of the FasL promoter [9,10]. We identified a non-canonical binding site (ATTCTCT) for
c-Myc
-Max heterodimers in the FasL promoter, which, when mutated, abolished activity in response to
c-Myc
. Exchange of the canonical
c-Myc
responsive elements (CACGTG) in the
ornithine decarboxylase
(
ODC
) promoter [11] with the non-canonical sequence in the FasL promoter generated an
ODC
-FasL promoter that was significantly more responsive to
c-Myc
than the wild-type
ODC
promoter. Our findings identify a precise physiological role for
c-Myc
in the induction of apoptosis as a transcriptional regulator of the FasL gene.
...
PMID:A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc. 1105 Mar 89
<< Previous
1
2
3
4
5
6
7
8
Next >>